Since the legalisation of medical cannabis in Australia in 2016, the medical application has been a hot topic in the media, across politics and in the medical health space.
Research and development is at the core of everything we do at ANTG, and it’s our role to provide you with evidence and tools to help make informed medical decisions.
We’re dedicated to discovering the full potential of cannabinoid medicines in treating disease and improving lives. The individual health and wellbeing of people are at the heart of everything we do.
That’s why we partner with leading scientists, medical institutions and research centres to improve medical knowledge and efficacy. Our research partners include the University of Newcastle and the National Institute for Complementary Medicines at Western Sydney University amongst many others. Together, we’re expanding our understanding of additional uses for cannabinoids, not only to help people but to shape the future of the industry.
We are also proud to have recently become the first Australian member of the Global Cannabis Partnership. The GCP is an international initiative that focuses on the establishment of worldwide corporate social responsibility (CSR) standards and informed consumption of legal cannabis.
Learn more about this exciting field in the articles below.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.